Get all your news in one place.
100's of premium titles.
One app.
Start reading
Fortune
Fortune
François Candelon, Maxime Courtaux, Max Männig, Vinit Patel

In synthetic biology, startups and incumbent companies should be partners, not foes

A large ball and a small ball balance one another on a scale. (Credit: Courtesy of Getty Images)

Two years ago, the synthetic biology start-up Geno decided to scale its process to manufacture a primary alcohol, BDO, from farm-grown materials such as sugarcane, sugar beets, and corn rather than petroleum-based substrates. The chemical is used in the manufacture of numerous products, and has grown into a $10-billion-plus a year market. While Geno’s bio-BDO performs just as well as the petroleum-based product and can be manufactured at a competitive price, its plant-based syn-bio process emits less than 10% of the greenhouse gases that industrial processes do, making it more sustainable. 

Although Geno (then called Genomatica) first produced BDO from plant sugars in 2008, its process faced many challenges in evolving from lab to scale. That’s why the San Diego-based firm strategically decided to work with seasoned incumbents such as DuPont Tate & Lyle Bio Products in 2013 to test its process; with Novamont, an Italian bio-plastics manufacturer, in 2016, to commercialize it; and then, with Qore—the Cargill-HELM joint venture—to manufacture its bio-BDO at scale. Qore plans to invest $300 million to build a syn-bio campus in Iowa by 2024, the centerpiece of which will be a 65,000-tons-per-annum bio-BDO plant—the world’s biggest—that will cater to around 2% of global BDO demand. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.